Revvity Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Revvity wird ein jährliches Gewinn- und Umsatzwachstum von 26.4% bzw. 6.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 26.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.1% betragen.

Wichtige Informationen

25.8%

Wachstumsrate der Gewinne

26.4%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	0%
Wachstumsrate der Einnahmen	6.2%
Zukünftige Eigenkapitalrendite	8.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	27 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BOVESPA:R1VT34 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3,173	402	914	810	11
12/31/2025	2,961	334	793	743	15
12/31/2024	2,776	246	549	630	14
6/30/2024	2,708	197	383	469	N/A
3/31/2024	2,726	183	97	175	N/A
12/31/2023	2,751	180	10	91	N/A
10/1/2023	2,796	213	-50	34	N/A
7/2/2023	2,837	250	153	227	N/A
4/2/2023	3,024	353	380	460	N/A
1/1/2023	3,312	513	594	680	N/A
10/2/2022	3,599	599	790	876	N/A
7/3/2022	3,748	637	932	1,030	N/A
4/3/2022	3,483	694	1,122	1,220	N/A
1/2/2022	3,828	889	1,325	1,411	N/A
10/3/2021	4,155	1,086	1,478	1,557	N/A
7/4/2021	4,257	1,155	1,380	1,455	N/A
4/4/2021	4,438	1,074	1,234	1,306	N/A
1/3/2021	2,663	631	829	892	N/A
10/4/2020	3,234	412	545	625	N/A
7/5/2020	2,977	294	444	521	N/A
4/5/2020	2,887	226	352	429	N/A
12/29/2019	2,884	228	282	363	N/A
9/29/2019	2,835	235	217	308	N/A
6/30/2019	2,802	251	199	294	N/A
3/31/2019	2,783	247	225	320	N/A
12/30/2018	2,778	237	218	311	N/A
9/30/2018	2,663	128	203	280	N/A
7/1/2018	2,543	149	178	245	N/A
4/1/2018	2,387	147	N/A	220	N/A
12/31/2017	2,257	157	N/A	288	N/A
10/1/2017	2,182	258	N/A	309	N/A
7/2/2017	2,142	215	N/A	324	N/A
4/2/2017	2,132	210	N/A	372	N/A
1/1/2017	2,116	216	N/A	351	N/A
10/2/2016	1,999	198	N/A	327	N/A
7/3/2016	2,048	199	N/A	314	N/A
4/3/2016	2,076	190	N/A	281	N/A
1/3/2016	2,105	189	N/A	287	N/A
10/4/2015	2,263	176	N/A	258	N/A
6/28/2015	2,241	164	N/A	261	N/A
3/29/2015	2,234	167	N/A	252	N/A
12/28/2014	2,070	130	N/A	282	N/A
9/28/2014	2,221	203	N/A	257	N/A
6/29/2014	2,201	201	N/A	242	N/A
3/30/2014	2,185	176	N/A	215	N/A
12/29/2013	2,158	174	N/A	159	N/A
9/29/2013	2,139	85	N/A	126	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: R1VT34Das prognostizierte Gewinnwachstum (26.4% pro Jahr) liegt über der Sparquote (9.9%).

Ertrag vs. Markt: R1VT34Die Erträge des Unternehmens (26.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt BR (16.3% pro Jahr).

Hohe Wachstumserträge: R1VT34Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: R1VT34Die Einnahmen des Unternehmens (6.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt BR (6.8% pro Jahr).

Hohe Wachstumseinnahmen: R1VT34Die Einnahmen des Unternehmens (6.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: R1VT34Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.1 %).

Revvity Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Recent updates

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity Board Declares Quarterly Dividend, Payable on November 8, 2024

Revvity, Inc. to Report Q2, 2024 Results on Jul 29, 2024

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024

Revvity Unveils A New Era of Automated Tuberculosis Testing

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development

Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.

PerkinElmer, Inc. Provides Earnings Guidance for the Full Year of 2023

PerkinElmer, Inc. Declares Regular Quarterly Dividend, Payable on May 12, 2023

PerkinElmer, Inc. to Report Q4, 2022 Results on Feb 14, 2023

PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns

PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

PerkinElmer, Inc. Declares a Regular Quarterly Dividend, Payable on February 10, 2023

PerkinElmer, Inc. to Report Q3, 2022 Results on Nov 08, 2022

PerkinElmer, Inc. Unveils Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing

Perkinelmer’S Oxford Immunotec Receives U.S. Fda Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

PerkinElmer, Inc. Announces Appointment of Maxwell Krakowiak as Senior Vice President, Effective September 6, 2022

New Mountain Capital, L.L.C. entered into a definitive agreement with the intention to acquire Applied, Food and Enterprise Services businesses of PerkinElmer, Inc. (NYSE:PKI) for $2.5 billion.

PerkinElmer, Inc. Elects Michelle McMurry-Heath to its Board of Directors

PerkinElmer, Inc. to Report Q2, 2022 Results on Aug 04, 2022

PerkinElmer, Inc.(NYSE:PKI) dropped from Russell 1000 Value-Defensive Index

Perkinelmer Introduces Next Generation, Automated Gas Chromatography Platform

PerkinElmer Expands Food Safety Testing Portfolio with AOAC Certified Microbial Count Plates

PerkinElmer, Inc. Launches BioQule NGS System to Automate Library Preparation

PerkinElmer, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2022

PerkinElmer, Inc. to Report Q1, 2022 Results on May 03, 2022

PerkinElmer, Inc. Expands in Vivo Instruments Portfolio with Hands-Free, High-throughput Vega® Widefield Preclinical Ultrasound Imaging System

PerkinElmer, Inc. Introduces First Ready-To-Use HTRF and AlphaLISA Assay Kits for CHO HCP Impurities Detection and Quantification

Perkinelmer, Inc. Launches ChemDraw V21 Software, Empowering Researchers to Rapidly Create Chemically Intelligent Microsoft Powerpoint Reports

PerkinElmer, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022

PerkinElmer, Inc. Declares Quarterly Dividend, Payable on May 13, 2022

PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021

PerkinElmer India Welcomes Everest Instruments as its Primary, In-Country Channel Partner for Milk and Dairy Testing Solutions

PerkinElmer Launches NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to Strengthen SARS-CoV-2 Surveillance

PerkinElmer, Inc. Launches Cloud Based Solution to Enable Remote Lab Management

PerkinElmer, Inc. Receives U.S. Food and Drug Administration Emergency Use Authorization for PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 Assay

PerkinElmer Expands Automated Mycotoxin Detection Kits Portfolio to Include All Major Mycotoxins

PerkinElmer, Inc.(NYSE:PKI) dropped from Russell 1000 Growth Index

PerkinElmer, Inc. (NYSE:PKI) completed the acquisition of Nexcelom Bioscience LLC from Ampersand Capital Partners.

PerkinElmer, Inc. (NYSE:PKI) entered into an agreement to acquire SIRION Biotech GmbH.

PerkinElmer, Inc. (NYSE:PKI) entered into an agreement to acquire Nexcelom Bioscience LLC for $260 million.

PerkinElmer, Inc. Provides Earnings Guidance for Second Quarter and Full Year 2021

Perkinelmer, Inc. Declares Regular Quarterly Dividend, Payable on August 6, 2021

Perkinelmer, Inc. Provides Revenue Guidance for the First Quarter Ended April 4, 2021

PerkinElmer Launches Industry-First CRM Reagent and Consumable Kit to Streamline Cannabis Pesticide Testing Workflows

PerkinElmer, Inc., Annual General Meeting, Apr 27, 2021